Bone Marrow Fibrosis research hub

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

This study looks at treating a bone marrow condition called myelofibrosis. We compare if a stem cell transplant, after starting with a medicine called ruxolitinib, is better than just continuing ruxolitinib for people who don't have a suitable donor.